ESPERION THERAPEUTICS INC NE's ticker is ESPR and the CUSIP is 29664W105. A total of 168 filers reported holding ESPERION THERAPEUTICS INC NE in Q3 2020. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,094 | +82.6% | 1,116,655 | +159.1% | 0.09% | +56.7% |
| Q2 2023 | $599 | +234.6% | 430,922 | +282.8% | 0.06% | +233.3% |
| Q1 2023 | $179 | +58.4% | 112,584 | +518.0% | 0.02% | +28.6% |
| Q4 2022 | $113 | -100.0% | 18,217 | -22.9% | 0.01% | -51.7% |
| Q3 2021 | $285,000 | -45.4% | 23,628 | +17.6% | 0.03% | -65.9% |
| Q4 2020 | $522,000 | +7.6% | 20,093 | +54.0% | 0.08% | +4.9% |
| Q3 2020 | $485,000 | -31.4% | 13,050 | -14.1% | 0.08% | +2.5% |
| Q2 2019 | $707,000 | +55.7% | 15,197 | +67.9% | 0.08% | +154.8% |
| Q3 2017 | $454,000 | +1.1% | 9,050 | -6.7% | 0.03% | +6.9% |
| Q2 2017 | $449,000 | -65.0% | 9,705 | -73.3% | 0.03% | -58.0% |
| Q1 2017 | $1,283,000 | +70.6% | 36,328 | +13.9% | 0.07% | +86.5% |
| Q3 2015 | $752,000 | +5.8% | 31,898 | +266.6% | 0.04% | +37.0% |
| Q2 2015 | $711,000 | – | 8,700 | – | 0.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 4,468,835 | $22,344,000 | 10.09% |
| Altium Capital Management LP | 2,515,785 | $12,579,000 | 3.47% |
| Deep Track Capital, LP | 5,641,668 | $28,208,000 | 1.99% |
| Paradigm Biocapital Advisors LP | 839,257 | $4,196,000 | 1.20% |
| SABBY MANAGEMENT, LLC | 940,400 | $4,702,000 | 0.68% |
| Monaco Asset Management SAM | 500,000 | $2,500,000 | 0.62% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 5,000,000 | $25,000,000 | 0.52% |
| CVI Holdings, LLC | 1,460,595 | $7,303,000 | 0.48% |
| PLATINUM INVESTMENT MANAGEMENT LTD | 2,713,176 | $13,566,000 | 0.38% |
| Rhenman & Partners Asset Management AB | 1,000,000 | $4,960,000 | 0.33% |